Clinical trials: Gastric Cancer, completed
Advanced Gastric Cancer
Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS
The urgent need for a new effective therapy with better safety profile for the metastatic gastric cancer patients and promising results observed so far in the studies with S-1 plus cisplatin combination in advanced gastric cancer…
- Trial name
- NCT00915382
- Testing
- S-1 and cisplatin
- Where
- South Korea
- Volunteers
- 625 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
The purpose of this study is: To observe the feasibility of biweekly oxaliplatin and infusional 5-fluorouracil (FU)/Leucovorin (LV) in patients with advanced gastric adenocarcinoma who have prior exposure to taxane…
- Trial name
- NCT00976768
- Testing
- oxaliplatin, 5-fluorouracil
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Resected Advanced Gastric Cancer
Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP
Despite the improvement of surgical resection as primary curative treatment for gastric cancer, more than 70% of patients with stage IIIB and IV disease undergoing radical primary tumor resection relapse and die within 5 years.
- Trial name
- NCT00976976
- Testing
- docetaxel, capecitabine, cisplatin
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Asan Medical Center
Gastric Cancer, Histone Deacetylase Inhibitor
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer.
- Trial name
- NCT01045538
- Testing
- Vorinostat, capecitabine, and cisplatin
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Venous Thromboembolism in Advanced Gastric Cancer Patients
Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is a common complication and leading cause of death in cancer patients.
- Trial name
- NCT01047618
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the growth of tumors like renal cell…
- Trial name
- NCT01049620
- Testing
- RAD001, Capecitabine, Oxaliplatin
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Metastatic or Recurrent Gastric Adenocarcinoma, Her-2 Positive Gastric Cancer
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or…
- Trial name
- NCT01396707
- Testing
- Herceptin+XELOX
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
- Trial name
- NCT01471470
- Testing
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1
This is a single-center, prospective, single-arm, open-label phase II study
- Trial name
- NCT01719549
- Testing
- Dovitinib
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Intestinal Microbiome After Gastrectomy
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are…
- Trial name
- DiGMA (NCT03418428)
- Where
- Lithuania
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Vilnius University
Advanced Gastric Cancer
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
This study is a single arm, single center phase II study of AZD5363 in combination with paclitaxel in patients with advanced gastric adenocarcinoma harboring PIK3CA mutation or amplification as a second line chemotherapy.
- Trial name
- NCT02451956
- Testing
- AZD5363, paclitaxel
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Samsung Medical Center
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil.
- Trial name
- NCT00515411
- Testing
- Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
- Where
- 15 sites in United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Breast Cancer
HER2-Peptide Vaccination of Patients With Solid Tumors
Investigation of peptide vaccination targeting HER2/neu in patients with metastasized breast or gastric cancer with moderate HER2/neu expression.
- Trial name
- HER2 (NCT02276300)
- Testing
- Cyclophosphamide, Sargramostim, HER2-Peptid-Vakzine
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Technical University of Munich
Gastric Cancer
Artificial Intelligence Versus Expert Endoscopists for Diagnosis of Gastric Cancer
Title: A single-center, retrospective randomized controlled trial of artificial intelligence (AI) versus expert endoscopists for diagnosis of gastric cancer in patients who underwent upper gastrointestinal endoscopy.
- Trial name
- NCT04040374
- Testing
- AI-based diagnosis, The expert endoscopists-based diagnosis
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Tokyo University
Metastatic Gastric Cancer
Genotype Guided Chemotherapy in Gastric Cancer Patients
In gastric cancer patients treated with 5-FU and cisplatin, higher tumor TS levels were associated with a less favorable response (29% vs. 68%; p=0.024).
- Trial name
- NCT02204306
- Testing
- TSER
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Central South University
Gastric Cancer
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Background: Gastric (stomach) cancer is a rare cancer. In most cases, by the time it has been diagnosed it has spread to other organs in the body and the chance of a cure is very small.
- Trial name
- NCT00941655
- Testing
- Oxaliplatin, Irinotecan, 5-Fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer, Gastroesophageal Junction Cancer
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
This single-arm, open-label study will evaluate the safety and efficacy of the combination oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy in the adjuvant setting in participants with curatively resected HER2+…
- Trial name
- TOXAG (NCT01748773)
- Testing
- Oxaliplatin, Radiation, Capecitabine
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer, Colorectal Cancer
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer
- Trial name
- NCT02574663
- Testing
- TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Gastric Cancer
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate progression-free survival in participants with gastric or gastroesophageal junction cancer who have had disease progression following first-line therapy who undergo treatment with…
- Trial name
- NCT01983878
- Testing
- Ramucirumab
- Where
- 11 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company